These results demonstrate that the administration of candesartan, a drug that suppresses PA-induced intracellular Ca2+ overload, in HFD-fed mice substantially reversed obesity-induced insulin resistance by improving postprandial insulin signaling. The gene discussed is INS; the disease is Insulin resistance.